Reducing Adenoviral Patient Infected Days

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 23, 2015

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2018

Conditions
ConjunctivitisAdenoviral Conjunctivitis
Interventions
DRUG

Betadine 5%

"One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions."

DRUG

Artificial Tears

One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.

Trial Locations (1)

63110

Mary Migneco, St Louis

All Listed Sponsors
collaborator

University of Alabama at Birmingham

OTHER

collaborator

Illinois College of Optometry

OTHER

collaborator

University of Illinois at Chicago

OTHER

collaborator

Northeastern State University

OTHER

collaborator

Ohio State University

OTHER

collaborator

Massachusetts Eye and Ear Infirmary

OTHER

collaborator

Brooke Army Medical Center

FED

collaborator

University of California, Berkeley

OTHER

collaborator

New England College of Optometry

OTHER

collaborator

Massachusetts College of Pharmacy and Health Science

OTHER

lead

Washington University School of Medicine

OTHER

NCT02472223 - Reducing Adenoviral Patient Infected Days | Biotech Hunter | Biotech Hunter